1887

Abstract

The activity of moxifloxacin was compared with ofloxacin and doxycycline against bacteria associated with periodontitis within a biofilm (single strain and mixed population) . MICs and minimal bactericidal concentrations (MBCs) of moxifloxacin, ofloxacin and doxycyline were determined against single strains and mixed populations in a planktonic state. Single-species biofilms of two and two strains and a multispecies biofilm consisting of 12 species were formed for 3 days. The minimal biofilm eradication concentrations (MBECs) were determined after exposing the biofilms to the antibacterials (0.002–512 µg ml) for 18 h, addition of nutrient broth for 3 days and subsequent subcultivation. Photographs were taken using confocal laser-scanning microscopy and scanning electron microscopy. The MICs and MBCs did not differ between ofloxacin and moxifloxacin against , whilst moxifloxacin was more active than the other tested antibacterials against anaerobes and the mixed population. The single-species biofilms were eradicated by moderate concentrations of the antibacterials, and the lowest MBECs were always found for moxifloxacin (2–8 µg ml). MBECs against the multispecies biofilms were 128, >512 and >512 µg ml for moxifloxacin, ofloxacin and doxycycline, respectively. In summary, moxifloxacin in a topical formulation may have potential as an adjunct to mechanical removal of the biofilms.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.065441-0
2014-02-01
2020-01-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/2/284.html?itemId=/content/journal/jmm/10.1099/jmm.0.065441-0&mimeType=html&fmt=ahah

References

  1. Ackermann G., Schaumann R., Pless B., Claros M. C., Goldstein E. J., Rodloff A. C.. ( 2000;). Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. . Eur J Clin Microbiol Infect Dis 19:, 228–232. [CrossRef][PubMed]
    [Google Scholar]
  2. Anonymous. ( 1996;). Consensus report periodontal diseases: pathogenesis and microbial factors. . Ann Periodontol 1:, 926–932. [CrossRef][PubMed]
    [Google Scholar]
  3. Apatzidou D. A., Kinane D. F.. ( 2010;). Nonsurgical mechanical treatment strategies for periodontal disease. . Dent Clin North Am 54:, 1–12. [CrossRef][PubMed]
    [Google Scholar]
  4. Ardila C. M., Granada M. I., Guzmán I. C.. ( 2010;). Antibiotic resistance of subgingival species in chronic periodontitis patients. . J Periodontal Res 45:, 557–563.[PubMed]
    [Google Scholar]
  5. Ashimoto A., Chen C., Bakker I., Slots J.. ( 1996;). Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions. . Oral Microbiol Immunol 11:, 266–273. [CrossRef][PubMed]
    [Google Scholar]
  6. Badet C., Quero F.. ( 2011;). The in vitro effect of manuka honeys on growth and adherence of oral bacteria. . Anaerobe 17:, 19–22. [CrossRef][PubMed]
    [Google Scholar]
  7. Barman Balfour J. A., Wiseman L. R.. ( 1999;). Moxifloxacin. . Drugs 57:, 363–373, discussion 374. [CrossRef][PubMed]
    [Google Scholar]
  8. Behra-Miellet J., Dubreuil L., Jumas-Bilak E.. ( 2002;). Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. . Int J Antimicrob Agents 20:, 366–374. [CrossRef][PubMed]
    [Google Scholar]
  9. Belibasakis G. N., Thurnheer T.. ( 2013;). Validation of antibiotic efficacy on in vitro subgingival biofilms. . J Periodontol 1–8. [CrossRef][PubMed]
    [Google Scholar]
  10. Beringer P. M., Owens H., Nguyen A., Benitez D., Rao A., D’Argenio D. Z.. ( 2012;). Pharmacokinetics of doxycycline in adults with cystic fibrosis. . Antimicrob Agents Chemother 56:, 70–74. [CrossRef][PubMed]
    [Google Scholar]
  11. Bland P. S., Goodson J. M., Gunsolley J. C., Grossi S. G., Otomo-Corgel J., Doherty F., Comiskey J. L.. ( 2010;). Association of antimicrobial and clinical efficacy: periodontitis therapy with minocycline microspheres. . J Int Acad Periodontol 12:, 11–19.[PubMed]
    [Google Scholar]
  12. Bosco J. M., Lopes B. M., Bosco A. F., Spolidorio D. M., Marcantonio R. A.. ( 2009;). Local application of tetracycline solution with a microbrush: an alternative treatment for persistent periodontitis. . Quintessence Int 40:, 29–40.[PubMed]
    [Google Scholar]
  13. Cachovan G., Böger R. H., Giersdorf I., Hallier O., Streichert T., Haddad M., Platzer U., Schön G., Wegscheider K., Sobottka I.. ( 2011;). Comparative efficacy and safety of moxifloxacin and clindamycin in the treatment of odontogenic abscesses and inflammatory infiltrates: a phase II, double-blind, randomized trial. . Antimicrob Agents Chemother 55:, 1142–1147. [CrossRef][PubMed]
    [Google Scholar]
  14. Dalhoff A., Schmitz F. J.. ( 2003;). In vitro antibacterial activity and pharmacodynamics of new quinolones. . Eur J Clin Microbiol Infect Dis 22:, 203–221.[PubMed]
    [Google Scholar]
  15. Decker E. M.. ( 2001;). The ability of direct fluorescence-based, two-colour assays to detect different physiological states of oral streptococci. . Lett Appl Microbiol 33:, 188–192. [CrossRef][PubMed]
    [Google Scholar]
  16. Di Bonaventura G., Spedicato I., D’Antonio D., Robuffo I., Piccolomini R.. ( 2004;). Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime. . Antimicrob Agents Chemother 48:, 151–160. [CrossRef][PubMed]
    [Google Scholar]
  17. Eick S., Pfister W.. ( 2004;). Efficacy of antibiotics against periodontopathogenic bacteria within epithelial cells: an in vitro study. . J Periodontol 75:, 1327–1334. [CrossRef][PubMed]
    [Google Scholar]
  18. Eick S., Schmitt A., Sachse S., Schmidt K. H., Pfister W.. ( 2004a;). In vitro antibacterial activity of fluoroquinolones against Porphyromonas gingivalis strains. . J Antimicrob Chemother 54:, 553–556. [CrossRef][PubMed]
    [Google Scholar]
  19. Eick S., Seltmann T., Pfister W.. ( 2004b;). Efficacy of antibiotics to strains of periodontopathogenic bacteria within a single species biofilm – an in vitro study. . J Clin Periodontol 31:, 376–383. [CrossRef][PubMed]
    [Google Scholar]
  20. Eick S., Straube A., Guentsch A., Pfister W., Jentsch H.. ( 2011;). Comparison of real-time polymerase chain reaction and DNA-strip technology in microbiological evaluation of periodontitis treatment. . Diagn Microbiol Infect Dis 69:, 12–20. [CrossRef][PubMed]
    [Google Scholar]
  21. EUCAST ( 2013;). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 3.0 b. European Committee on Antimicrobial Susceptibility Testing.
  22. Feres M., Haffajee A. D., Allard K., Som S., Goodson J. M., Socransky S. S.. ( 2002;). Antibiotic resistance of subgingival species during and after antibiotic therapy. . J Clin Periodontol 29:, 724–735. [CrossRef][PubMed]
    [Google Scholar]
  23. Flemmig T. F., Petersilka G., Völp A., Gravemeier M., Zilly M., Mross D., Prior K., Yamamoto J., Beikler T.. ( 2011;). Efficacy and safety of adjunctive local moxifloxacin delivery in the treatment of periodontitis. . J Periodontol 82:, 96–105. [CrossRef][PubMed]
    [Google Scholar]
  24. Goodson J. M.. ( 2003;). Gingival crevice fluid flow. . Periodontol 2000 31:, 43–54. [CrossRef][PubMed]
    [Google Scholar]
  25. Guentsch A., Jentsch H., Pfister W., Hoffmann T., Eick S.. ( 2008;). Moxifloxacin as an adjunctive antibiotic in the treatment of severe chronic periodontitis. . J Periodontol 79:, 1894–1903. [CrossRef][PubMed]
    [Google Scholar]
  26. Guo Y., Nguyen K. A., Potempa J.. ( 2010;). Dichotomy of gingipains action as virulence factors: from cleaving substrates with the precision of a surgeon’s knife to a meat chopper-like brutal degradation of proteins. . Periodontol 2000 54:, 15–44. [CrossRef][PubMed]
    [Google Scholar]
  27. Haas A. N., de Castro G. D., Moreno T., Susin C., Albandar J. M., Oppermann R. V., Rösing C. K.. ( 2008;). Azithromycin as an adjunctive treatment of aggressive periodontitis: 12-months randomized clinical trial. . J Clin Periodontol 35:, 696–704. [CrossRef][PubMed]
    [Google Scholar]
  28. Han B., Emingil G., Özdemir G., Tervahartiala T., Vural C., Atilla G., Baylas H., Sorsa T.. ( 2012;). Azithromycin as an adjunctive treatment of generalized severe chronic periodontitis: clinical, microbiologic, and biochemical parameters. . J Periodontol 83:, 1480–1491. [CrossRef][PubMed]
    [Google Scholar]
  29. Hardy D., Amsterdam D., Mandell L. A., Rotstein C.. ( 2000;). Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of Gram-positive cocci. . Antimicrob Agents Chemother 44:, 802–805. [CrossRef][PubMed]
    [Google Scholar]
  30. Henderson B., Nair S. P., Ward J. M., Wilson M.. ( 2003;). Molecular pathogenicity of the oral opportunistic pathogen Actinobacillus actinomycetemcomitans. . Annu Rev Microbiol 57:, 29–55. [CrossRef][PubMed]
    [Google Scholar]
  31. Herrera D., Alonso B., León R., Roldán S., Sanz M.. ( 2008;). Antimicrobial therapy in periodontitis: the use of systemic antimicrobials against the subgingival biofilm. . J Clin Periodontol 35: (Suppl), 45–66. [CrossRef][PubMed]
    [Google Scholar]
  32. Higashi K., Seike M., Mitani Y., Morisaki K., Hayashi S., Kitamura M., Fujimoto N., Kimura S., Ebisu S., Okada H.. ( 1989;). Concentration of ofloxacin in human gingival crevicular fluid after oral administration of Tarivid. . J Periodontal Res 24:, 409–411. [CrossRef][PubMed]
    [Google Scholar]
  33. Hofer D., Meier A., Sener B., Guggenheim B., Attin T., Schmidlin P. R.. ( 2011;). Biofilm reduction and staining potential of a 0.05% chlorhexidine rinse containing essential oils. . Int J Dent Hyg 9:, 60–67. [CrossRef][PubMed]
    [Google Scholar]
  34. Høiby N., Bjarnsholt T., Givskov M., Molin S., Ciofu O.. ( 2010;). Antibiotic resistance of bacterial biofilms. . Int J Antimicrob Agents 35:, 322–332. [CrossRef][PubMed]
    [Google Scholar]
  35. Kleinfelder J. W., Mueller R. F., Lange D. E.. ( 2000;). Fluoroquinolones in the treatment of Actinobacillus actinomycetemcomitans-associated periodontitis. . J Periodontol 71:, 202–208. [CrossRef][PubMed]
    [Google Scholar]
  36. Kolenbrander P. E.. ( 2000;). Oral microbial communities: biofilms, interactions, and genetic systems. . Annu Rev Microbiol 54:, 413–437. [CrossRef][PubMed]
    [Google Scholar]
  37. Kolenbrander P. E., Palmer R. J. Jr, Periasamy S., Jakubovics N. S.. ( 2010;). Oral multispecies biofilm development and the key role of cell-cell distance. . Nat Rev Microbiol 8:, 471–480. [CrossRef][PubMed]
    [Google Scholar]
  38. Kuck E. M., Bouter K. P., Hoekstra J. B., Conemans J. M., Diepersloot R. J.. ( 1998;). Tissue concentrations after a single-dose, orally administered ofloxacin in patients with diabetic foot infections. . Foot Ankle Int 19:, 38–40. [CrossRef][PubMed]
    [Google Scholar]
  39. Mouratidou A., Karbach J., d’Hoedt B., Al-Nawas B.. ( 2011;). Antibiotic susceptibility of cocultures in polymicrobial infections such as peri-implantitis or periodontitis: an in vitro model. . J Periodontol 82:, 1360–1366. [CrossRef][PubMed]
    [Google Scholar]
  40. Müller H. P., Heinecke A., Borneff M., Kiencke C., Knopf A., Pohl S.. ( 1998;). Eradication of Actinobacillus actinomycetemcomitans from the oral cavity in adult periodontitis. . J Periodontal Res 33:, 49–58. [CrossRef][PubMed]
    [Google Scholar]
  41. Pascual A., García I., Ballesta S., Perea E. J.. ( 1999;). Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. . Antimicrob Agents Chemother 43:, 12–15.[PubMed]
    [Google Scholar]
  42. Roveta S., Schito A. M., Marchese A., Schito G. C.. ( 2007;). Activity of moxifloxacin on biofilms produced in vitro by bacterial pathogens involved in acute exacerbations of chronic bronchitis. . Int J Antimicrob Agents 30:, 415–421. [CrossRef][PubMed]
    [Google Scholar]
  43. Sgolastra F., Petrucci A., Gatto R., Monaco A.. ( 2011;). Effectiveness of systemic amoxicillin/metronidazole as an adjunctive therapy to full-mouth scaling and root planing in the treatment of aggressive periodontitis: a systematic review and meta-analysis. . J Periodontol 83:, 731–743. [CrossRef][PubMed]
    [Google Scholar]
  44. Sgolastra F., Gatto R., Petrucci A., Monaco A.. ( 2012;). Effectiveness of systemic amoxicillin/metronidazole as adjunctive therapy to scaling and root planing in the treatment of chronic periodontitis: a systematic review and meta-analysis. . J Periodontol 83:, 1257–1269. [CrossRef][PubMed]
    [Google Scholar]
  45. Shchipkova A. Y., Nagaraja H. N., Kumar P. S.. ( 2010;). Subgingival microbial profiles of smokers with periodontitis. . J Dent Res 89:, 1247–1253. [CrossRef][PubMed]
    [Google Scholar]
  46. Socransky S. S., Haffajee A. D.. ( 2005;). Periodontal microbial ecology. . Periodontol 2000 38:, 135–187. [CrossRef][PubMed]
    [Google Scholar]
  47. Speciale A., Musumeci R., Blandino G., Milazzo I., Caccamo F., Nicoletti G.. ( 2002;). Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates. . Int J Antimicrob Agents 19:, 111–118. [CrossRef][PubMed]
    [Google Scholar]
  48. Stass H., Dalhoff A., Kubitza D., Schühly U.. ( 1998;). Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. . Antimicrob Agents Chemother 42:, 2060–2065.[PubMed]
    [Google Scholar]
  49. Stoller N. H., Johnson L. R., Trapnell S., Harrold C. Q., Garrett S.. ( 1998;). The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. . J Periodontol 69:, 1085–1091. [CrossRef][PubMed]
    [Google Scholar]
  50. Ta C. N., He L., Nguyen E., De Kaspar H. M.. ( 2006;). Prospective randomized study determining whether a 3-day application of ofloxacin results in the selection of fluoroquinolone-resistant coagulase-negative Staphylococcus. . Eur J Ophthalmol 16:, 359–364.[PubMed]
    [Google Scholar]
  51. Takahashi N., Ishihara K., Kato T., Okuda K.. ( 2007;). Susceptibility of Actinobacillus actinomycetemcomitans to six antibiotics decreases as biofilm matures. . J Antimicrob Chemother 59:, 59–65. [CrossRef][PubMed]
    [Google Scholar]
  52. Tomasi C., Wennström J. L.. ( 2011;). Locally delivered doxycycline as an adjunct to mechanical debridement at retreatment of periodontal pockets: outcome at furcation sites. . J Periodontol 82:, 210–218. [CrossRef][PubMed]
    [Google Scholar]
  53. Tonetti M. S., Lang N. P., Cortellini P., Suvan J. E., Eickholz P., Fourmousis I., Topoll H., Vangsted T., Wallkamm B.. ( 2012;). Effects of a single topical doxycycline administration adjunctive to mechanical debridement in patients with persistent/recurrent periodontitis but acceptable oral hygiene during supportive periodontal therapy. . J Clin Periodontol 39:, 475–482. [CrossRef][PubMed]
    [Google Scholar]
  54. Torum B., Block S. L., Avila H., Montiel F., Oliva A., Quintanilla W., Duncanson F., Cantrell H. F., Riefler J.. & other authors ( 2004;). Efficacy of ofloxacin otic solution once daily for 7 days in the treatment of otitis externa: a multicenter, open-label, phase III trial. . Clin Ther 26:, 1046–1054. [CrossRef][PubMed]
    [Google Scholar]
  55. Van der Weijden G. A., Timmerman M. F.. ( 2002;). A systematic review on the clinical efficacy of subgingival debridement in the treatment of chronic periodontitis. . J Clin Periodontol 29: (Suppl 3), 55–71. [CrossRef][PubMed]
    [Google Scholar]
  56. van Winkelhoff A. J., Herrera D., Oteo A., Sanz M.. ( 2005;). Antimicrobial profiles of periodontal pathogens isolated from periodontitis patients in The Netherlands and Spain. . J Clin Periodontol 32:, 893–898. [CrossRef][PubMed]
    [Google Scholar]
  57. Yamagami H., Takamori A., Sakamoto T., Okada H.. ( 1992;). Intrapocket chemotherapy in adult periodontitis using a new controlled-release insert containing ofloxacin (PT-01). . J Periodontol 63:, 2–6. [CrossRef][PubMed]
    [Google Scholar]
  58. Yashima A., Gomi K., Maeda N., Arai T.. ( 2009;). One-stage full-mouth versus partial-mouth scaling and root planing during the effective half-life of systemically administered azithromycin. . J Periodontol 80:, 1406–1413. [CrossRef][PubMed]
    [Google Scholar]
  59. Zilberman M., Elsner J. J.. ( 2008;). Antibiotic-eluting medical devices for various applications. . J Control Release 130:, 202–215. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.065441-0
Loading
/content/journal/jmm/10.1099/jmm.0.065441-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error